Population Health Partners, an investment company focused on innovative therapeutics, and ARCH Venture Partners, a company providing seed / early stage venture capital, led a $290m seed and Series A round in Metsera, a clinical-stage biopharmaceutical company, with participation from F-Prime Capital, GV, Mubadala Capital, Newpath Partners, and SoftBank Vision Fund 2. “We are in the early days of an incredibly exciting new era of innovation in weight loss and obesity associated diseases. Metsera’s portfolio is focused beyond the current generation of market leaders to address the full spectrum of future weight loss therapeutic needs, including effective weight maintenance, preserving muscle, less-frequent dosing, and better efficacy, tolerability and patient access,” Kristina Burow, ARCH Venture Partners Managing Director.